- Home
- TLS vs HURA Comparison
TLS vs HURA Comparison
Compare TLS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- HURA
- Stock Information
- Founded
- TLS 1969
- HURA 2009
- Country
- TLS United States
- HURA United States
- Employees
- TLS N/A
- HURA N/A
- Industry
- TLS EDP Services
- HURA
- Sector
- TLS Technology
- HURA
- Exchange
- TLS Nasdaq
- HURA Nasdaq
- Market Cap
- TLS 185.9M
- HURA 171.7M
- IPO Year
- TLS 2020
- HURA N/A
- Fundamental
- Price
- TLS $2.52
- HURA $2.55
- Analyst Decision
- TLS Buy
- HURA Strong Buy
- Analyst Count
- TLS 6
- HURA 2
- Target Price
- TLS $3.94
- HURA $11.50
- AVG Volume (30 Days)
- TLS 434.3K
- HURA 128.8K
- Earning Date
- TLS 08-08-2025
- HURA 08-15-2025
- Dividend Yield
- TLS N/A
- HURA N/A
- EPS Growth
- TLS N/A
- HURA N/A
- EPS
- TLS N/A
- HURA N/A
- Revenue
- TLS $109,269,000.00
- HURA N/A
- Revenue This Year
- TLS $35.76
- HURA N/A
- Revenue Next Year
- TLS $26.83
- HURA $69.15
- P/E Ratio
- TLS N/A
- HURA N/A
- Revenue Growth
- TLS N/A
- HURA N/A
- 52 Week Low
- TLS $1.83
- HURA $1.80
- 52 Week High
- TLS $4.82
- HURA $13.13
- Technical
- Relative Strength Index (RSI)
- TLS 41.90
- HURA N/A
- Support Level
- TLS $2.48
- HURA N/A
- Resistance Level
- TLS $2.88
- HURA N/A
- Average True Range (ATR)
- TLS 0.12
- HURA 0.00
- MACD
- TLS -0.02
- HURA 0.00
- Stochastic Oscillator
- TLS 2.67
- HURA 0.00
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.